Sugi Predict

Sugi Predict / Compounds / SCHEMBL8089358

SCHEMBL8089358

SCHEMBL8089358

O=C(O)C(F)(F)c1ccccc1OCC(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 3/20 0.49
▸ RXRB P28702 3/20 0.49
▸ RXRG P48443 3/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ PPARG P37231 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ S1PR2 O95136 1/20 0.46
▸ S1PR4 O95977 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ XBP1 P17861 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PAX8 Q06710 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ S1PR3 Q99500 1/20 0.46
▸ S1PR5 Q9H228 1/20 0.46
▸ S1PR1 P21453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30087620 0.85 RXRA (0.44) RXRARXRBRXRGMRGPRX4NPSR1
SCHEMBL17420741 0.83 GLA (0.53) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL30628253 0.83 GLA (0.53) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL17420746 0.83 MEN1 (0.43) RXRAMRGPRX4NPSR1PPARGGAA
SCHEMBL8088868 0.83 S1PR1 (0.47) RXRARXRBRXRGMRGPRX4NPSR1
SCHEMBL30628340 0.82 ALDH1A1 (0.44) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL17420709 0.82 ALDH1A1 (0.44) RXRARXRBRXRGMRGPRX4PPARG
Hydrochloric Acid SCHEMBL28379228 0.81 ALDH1A1 (0.43) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL30628230 0.81 RXRA (0.43) RXRARXRBRXRGMRGPRX4NPSR1
SCHEMBL17420555 0.81 RXRA (0.43) RXRARXRBRXRGMRGPRX4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3594211-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2023-10-25 — — EP disclosed
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2022-12-08 — — US disclosed
US-11241423-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2022-02-08 — — US disclosed
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2020-05-28 — — US disclosed
CN-111170991-A Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2020-05-19 — — CN disclosed
CN-106660991-B Antiproliferative compounds and methods of use thereof 细胞基因公司 2020-03-13 — — CN disclosed
EP-3166937-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2019-09-04 — — EP disclosed
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-08-09 — — US disclosed
US-9968596-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2018-05-15 — — US disclosed
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-01-25 — — US disclosed
US-9808451-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2017-11-07 — — US disclosed
EP-3166937-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF Celgene Corporation (US) 2017-05-17 — — EP disclosed
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2017-01-12 — — US disclosed
US-9499514-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2016-11-22 — — US disclosed
WO-2016007848-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION (US) 2016-01-14 — — WO disclosed
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION 2016-01-14 — — US disclosed
US-6090805-A Tocolytic oxytocin receptor antagonists MERCK & CO., INC. (US) 2000-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885
US-11241423-B2 Antiproliferative compounds and methods of use thereof MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX RXRA 881/4885RXRB 1052/4885RXRG 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.